Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Y-mAbs Therapeutics Q1 2024 GAAP EPS $(0.15) Beats $(0.16) Estimate, Sales $19.931M Miss $22.220M Estimate

Author: Benzinga Newsdesk | May 07, 2024 05:43pm
Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.16) by 6.25 percent. This is unchanged from the same period last year. The company reported quarterly sales of $19.931 million which missed the analyst consensus estimate of $22.220 million by 10.30 percent. This is a 1.58 percent decrease over sales of $20.251 million the same period last year.

Posted In: YMAB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist